Improvement of Pretibial Myxedema Following Administration of Teprotumumab

Pretibial myxedema (PTM) is a rare complication of Graves' disease. It is characterized by non-pitting edema with hyperpigmented hyperkeratotic papules and plaques on bilateral lower legs. Effective treatments for patients with PTM are lacking. The etiology of PTM is unknown; however, it may be similar to the mechanism of thyroid-associated ophthalmopathy (TAO). Activated fibroblasts produce inflammatory cytokines and synthesize excessive glycosaminoglycans (GAG) that accumulate in the dermis and subcutaneous tissue. A recent, novel pathway implicates IGF-1 receptor as a mediator in this process. We present two patients with refractory PTM that improved following treatment with teprotumumab, an IGF-1 receptor inhibitor approved for use in TAO. J Drugs Dermatol. 2022;21(11):1252-1254. doi:10.36849/JDD.6854.



Work Title Improvement of Pretibial Myxedema Following Administration of Teprotumumab
Open Access
  1. Abigail Washington
  2. Hannah Nam
  3. Michelle Pitch
  4. Bryan Anderson
  5. Jennifer Stokes
  6. Matthew Helm
License In Copyright (Rights Reserved)
Work Type Article
  1. Journal of Drugs in Dermatology
Publication Date October 24, 2022
Publisher Identifier (DOI)
Deposited March 25, 2024




This resource is currently not in any collection.

Work History

Version 1

  • Created
  • Added pretibial_myxedema.pdf
  • Added Creator Abigail Washington
  • Added Creator Hannah Nam
  • Added Creator Michelle Pitch
  • Added Creator Bryan Anderson
  • Added Creator Jennifer Stokes
  • Added Creator Matthew Helm
  • Published
  • Updated
  • Updated Publication Date Show Changes
    Publication Date
    • 2022-11-01
    • 2022-10-24